Zobrazeno 1 - 10 of 38 pro vyhledávání: '"H. Haltmayer"'
1
Akademický článek
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
Autor: M. Schwarz, C. Schwarz, A. Schütz, C. Schwanke, E. Krabb, R. Schubert, S.-T. Liebich, D. Bauer, L. Burghart, L. Brinkmann, E. Gutic, T. Reiberger, H. Haltmayer, M. Gschwantler
Publikováno v: Journal of Virus Eradication, Vol 9, Iss 1, Pp 100319- (2023)
Background & aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation
Externí odkaz: https://doaj.org/article/fbaf3371873741dea6c3a1ebf21e4342
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy
Autor: E. Gutic, Cornelia Schwanke, A. Schütz, T Lang, Roxana Pirker, Caroline Schmidbauer, H. Haltmayer, Michael Schwarz, Thomas Reiberger, Raphael Schubert, Michael Gschwantler
Publikováno v: PLoS ONE, Vol 16, Iss 6, p e0252274 (2021)
PLoS ONE
Background & aims We evaluated the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in difficult-to-treat PWIDs with presumed high risk for non-adherence to antiviral therapy using an innovative concept involving their opioid agonist therapy (OAT) f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61cd15a59597b97999cd3354fe3c428f
https://doaj.org/article/9b1adb9e5f5f407f81472ebb32218777
Zobrazit plný text záznamu
4
Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals
Autor: S Moser, T Lang, M Schleicher, E. Gutic, Michael Gschwantler, A. Schütz, J Luhn, H. Haltmayer, R. Schubert, C. Schwanke
Publikováno v: Journal of Viral Hepatitis. 25:870-873
An important subgroup of people who inject drugs (PWID) receiving opioid agonist therapy (OAT) cannot be treated in the setting of a hepatology centre and would not regularly ingest their medication when handed to them for self-administration. Our hy
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbb59886b635864c331b6f1675e0d49
https://doi.org/10.1111/jvh.12857
Zobrazit plný text záznamu
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria
Autor: Cornelia Schwanke, T Lang, Raphael Schubert, J Luhn, H. Haltmayer, Michael Gschwantler, Thomas Reiberger, E. Gutic, Roxana Pirker, Caroline Schmidbauer, A. Schütz
Publikováno v: PLoS ONE, Vol 15, Iss 3, p e0229239 (2020)
PLoS ONE
Background Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have facilitated sustained virologic response (SVR) rates >90% in clinical studies. Yet, real life data regarding DAA treatment in people who inject drugs (PWIDs) a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e6bbcde51de91e35cd48292da91a6f1
https://doi.org/10.1371/journal.pone.0229239
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje